GHK-Cu 100 mg reconstitution calculator

The same water makes this vial twice as concentrated as the 50 mg vial. With 2 mL it’s 50 mg/mL, so each unit on a U-100 syringe holds 500 mcg, against 250 mcg in the 50 mg vial. With 5 mL it’s 20 mg/mL (200 mcg per unit). Matching strengths takes twice the water: 100 mg in 5 mL and 50 mg in 2.5 mL are both 20 mg/mL. Units worked out for one vial size don’t carry over to the other, so recalculate whenever the vial size or the water changes. And 5 mL only fits a vial that holds at least that much.

The human evidence for GHK-Cu is small and topical. A systematic review through March 2026 found 20 studies, 18 of them preclinical and 2 randomized trials, and noted “a limited number of well-designed clinical trials” (Aesthet Surg J, 2026). Another 2026 review concludes that GHK-Cu “should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug” (Pharmaceutics, 2026). The one recruiting trial tests a topical gel on small skin wounds and has no findings posted yet (ClinicalTrials.gov). A ClinicalTrials.gov search on October 16, 2026 found 3 GHK-Cu studies, none testing it as an injection.

GHK-Cu’s compounding status changed twice this year. The FDA removed it from Category 1 on April 22, 2026, after the nominations were withdrawn. On May 5, 2026, one nominator said it meant to withdraw only its injectable nomination and keep the non-injectable one, so the FDA put non-injectable GHK-Cu back in Category 1 (FDA). The FDA plans to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu belongs on the 503A bulks list. No date is set yet, and the committee’s recommendations are non-binding (FDA).